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ABSTRACT
Background: Vitamin B12 and folic acid (referred to as
vitamin supplementation) improves the toxicity profile
of pemetrexed containing regimens. Low baseline
vitamin B12 and folate levels are reflected in a raised
total homocysteine level (HC). Studies have suggested
that pretreatment HC levels predict neutropenia toxicity.
We have tested supplementation with vitamin B12 and
folate in non-pemetrexed platinum-based regimens to
decrease treatment-related toxicity and looked for a
correlation between toxicity and change in
homocysteine levels.
Patient and method: Eighty-three patients with
advanced lung cancer and malignant mesothelioma were
randomly assigned to receive platinum-based
chemotherapy with (arm A) or without (arm B) vitamin
B12 and folic acid supplementation. The primary end point
was grade 3/4 neutropenia and death within 30 days of
treatment. Secondary end points included quality of life,
overall survival (OS) and the relationship between baseline
and post supplementation HC levels and toxicity.
Results: In the intention-to-treat population, no
significant difference was seen between the two groups
with respect to chemotherapy-induced grade 3/4
neutropenia and death within 30 days of chemotherapy
(36% vs 37%; p=0.966, emesis (2% vs 6%; p=0.9) or OS
(12.3 months vs 7 months; p=0.41). There was no
significant difference in survival rates by baseline HC level
(p=0.9). Decrease in HC with vitamin supplementation
was less frequent than expected. High baseline HC levels
decreased with vitamin supplementation in only 9/36
(25%) patients (successful supplementation). Post hoc
analysis showed that patients in arm Awho were
successfully supplemented (9/36=25%) had less
neutropenic toxicity (0% vs 69%; p=0.02) compared to
unsupplemented patients.
Conclusions: The addition of vitamin B12 and folic acid
to platinum-containing regimens did not overall improve
the toxicity, quality of life or OS. Rates of grade 3/4
neutropenia at 36/37% was as predicted. Further studies
to increase the rate of successful supplementation and to
further test the biomarker potential of post
supplementation HC levels in predicting chemotherapy-
induced neutropenia in platinum-based chemotherapy are
warranted.
Trial registration number: EudracCT 2005-002736-10
ISRCTN8734355.
BACKGROUND
Folate and vitamin B12 supplementation with
chemotherapy
Up to half of lung patients with cancer with
advanced disease can be malnourished, on
the basis of body mass index.1 There a
KEY MESSAGES
▸ In this un-blinded, randomised, phase II study
83 patients with advanced lung cancer and
malignant mesothelioma were assigned to receive
platinum-based chemotherapy with or without
vitamin B12 and folic acid supplementation.
▸ No significant difference was seen between the
two groups with respect to chemotherapy-
induced grade 3/4 neutropenia and death within
30 days of chemotherapy (36% vs 37%;
p=0.966) emesis (2% vs 6%; p=0.9) or overall
survival (12.3 months vs 7.0 months; p=0.41).
▸ High baseline homocysteine levels decreased
with vitamin supplementation in only 9/36 (25%)
patients. Post hoc analysis showed that patients
in arm A who were successfully supplemented
had less neutropenic toxicity compared to unsup-
plemented patients (0% vs 69%; p=0.02).
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number of potential reasons for this including poor
diet, cancer-induced nausea, paraneoplastic processes
and as a result of chronic smoking. Palliative chemother-
apy is associated with grade 3/4 rates of neutropenia
between 20% and 40%. There appears to be little differ-
ence in rates between the different carboplatin and cis-
platin regimens commonly used in non-small cell lung
cancer (NSCLC).2 3 The incidence of toxicity is similar
when the same regimens are used in malignant meso-
thelioma (MM).4 The incidence is higher in regimens
used in small cell lung cancer (SCLC) and in second-
line NSCLC.5 6
Some preclinical trials have highlighted the impact of
folate supplements on chemotherapy-induced toxicity and
clinical response. Branda et al7 found that survival was signiﬁ-
cantly better in folate-supplemented rats receiving cyclophos-
phamide and 5-FU and this group developed less host
toxicity compared to their folate deﬁcient counterparts. The
authors of the study hypothesised that the mechanism
behind the interaction between folate metabolism and
chemotherapy may be secondary to the relationship between
folate status and glutathione level, which has been shown to
correlate with chemotherapy toxicity.8 9
Pemetrexed containing regimes have been established as
the standard of care for the treatment of MM and non-small
cell lung cancer (NSCLC). The use of vitamin B12 and folic
acid has been shown to decrease toxicity.4 This is logical
given the inhibitory actions of pemetrexed in the folate
pathway. In Vogelzang et al’s trial of pemetrexed and cipla-
tin versus cisplatin alone in mesothelioma the incidence of
grade 3 and 4 neutropenia in the cisplatin/pemetrexed
arm was reduced from 41.4% to 23.2% (p=0.011) with
vitamin supplementation. Febrile neutropenia was reduced
from 5.2% to 0.6% (p=0.53).4 Interestingly however vitamin
supplementation also appeared to beneﬁt patients receiving
cisplatin alone. There has been little further investigation of
the role of folate and vitamin B12 supplementation in non-
pemetrexed containing regimes despite this clinical and
preclinical data.
Homocysteine levels as a marker of folate and vitamin B12
supplementation
Niyikiza et al carried out an analysis of pemetrexed-treated
patients to identify predictive factors for severe toxicity.
The results showed that pretreatment total plasma homo-
cysteine (HC) levels signiﬁcantly predicted severe
thrombocytopenia and neutropenia and subsequent sup-
plementation with vitamin B12 and folate reduced the inci-
dence and severity of such toxicities without affecting
efﬁcacy. The normal range in this study was 7.5–11.5 μM/L
in line with reports from cardiovascular study popula-
tions.10 High baseline homocysteine levels are associated
with folate and vitamin B12 deﬁciency.
11 Patients with
high baseline HC level were found in other studies to
have a high risk of severe haematological toxicity and
vitamin-supplemented patients tended to improve or
lower their concentrations of HC.10–12 Since total plasma
HC level is affected by a series of genetic, physiological,
lifestyle and clinical factors, Refsum et al13 have proposed
that, in routine clinical setting, signiﬁcant change in total
plasma HC should be deﬁned as a change of greater than
25% to 30% between samples collected on two occasions.
In this single centre, unblinded phase II randomised
study, the aim was to assess the impact of vitamin B12 and
folic acid supplementation on non-pemetrexed-based
chemotherapy-related neutropenic events and to determine
the potential role of using total plasma HC level before and
after vitamin B12 and folic acid supplementation (using
30% reduction of HC level as a cut-off for successful supple-
mentation) as a predictive biomarker of toxicity.
PATIENTS AND METHODS
Patients with NSCLC, SCLC or mesothelioma, who were
suitable for platinum-based chemotherapy, were eligible
for inclusion into the study if they fulﬁlled the following
criteria: age>18 years, histologically or cytologically con-
ﬁrmed NSCLC, SCLC or mesothelioma; an Eastern
Cooperative Oncology Group (ECOG) performance
status (PS) of 0–2; adequate organ function deﬁned as
an absolute neutrophil count >1.5×109/L, white cell
count >3×109/L, platelet count >100×109/L, serum cre-
atinine ≤1.25 upper level of normal, creatinine clear-
ance >50 mL/min (EDTA) or >60 mL/min (Cockroft
and Gault formula) for cisplatin or >40 mL/min for car-
boplatin; estimated life expectancy of at least 12 weeks.
Patients were excluded if they had an active infection,
inability or unwillingness to take vitamin supplementa-
tion, had taken any vitamins within the past 28 days or
receiving concomitant radical chemotherapy and radio-
therapy or antiepileptic treatment. All patients provided
a signed informed consent before screening for the
trial.
Patients were randomly assigned in a 1:1 ratio to arm A
(with vitamin supplementation) or arm B (chemotherapy
alone, no vitamin supplementation), which represented
treatment with or without vitamin supplementation,
respectively. Randomisation was carried out by telephone
through the Institute of Cancer Research Clinical Trial
and Statistics unit. Computer-generated permuted blocks
were used and stratiﬁcation was by centre. Block sizes were
4 and 6 (random). Vitamins were given on day of random-
isation and chemotherapy was scheduled to begin at least
7 days later.
All eligible patients with NSCLC, SCLC and MM
received platinum-based treatment with cisplatin dosed at
75 mg/m2 or carboplatin area under the curve (AUC5).
One of the following regimens was adopted for this study
at the discretion of the investigator: mitomycin-C plus
vinblastine, vinorelbine, docetaxel, gemcitabine or etopo-
side with cisplatin or carboplatin. A total of up to six cycles
of chemotherapy were administered and patients were
allowed to receive full supportive care therapies concomi-
tantly, except for growth factors as a prophylactic measure,
during the study. Palliative radiation therapy was permitted
for irradiating small areas of painful metastases that could
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not be managed adequately using systemic or local anal-
gesia. Study treatment was discontinued if other forms of
speciﬁc anti-tumour therapy were needed.
Patients randomised to arm A received oral folic acid
400 μg daily for at least 1 week prior to the ﬁrst cycle of
treatment and continued until 3 weeks after the last
dose of chemotherapy. Vitamin B12 1 mg was adminis-
tered as an intramuscular injection before treatment
and every 9 weeks until 3 weeks after last dose.
Compliance with vitamins was assessed at each treatment
cycle by direct questioning by the research nurses.
Patients randomised to arm B received no vitamin sup-
plementation and patients were assessed three weekly to
ensure additional ‘over the counter’ vitamin supplemen-
tation was not taken.
Blood samples for HC levels were taken after consent
during screening (before randomisation) on two occa-
sions and after at least 1 week of vitamins that is, on the
day of initiation of systemic therapy. Success of supple-
mentation was determined by comparing the two values
and was deﬁned as at least a 30% decrease in the HC
level. CT scans were obtained at screening and every
6 weeks during the study, 21 days after the last dose of
chemotherapy and at follow-up every 3 months.
All participants completed EORTC QLQ-C30 (V.3)
and Lung module QLQ-LC13 prior to start of chemo-
therapy, at 6 weeks and every 3 months post treatment as
appropriate until relapse or until 1 year post
randomisation.
Safety was monitored by physical examination, haematol-
ogy and biochemistry tests; assessment of ECOG PS and
adverse event reporting, based on the National Cancer
Institute Common Terminology Criteria for Adverse Events
(CTCAE), V.3.0, before each cycle of chemotherapy. Full
blood count including measurement of absolute neutrophil
count was assessed at Day 1 and Day 8–10 of every chemo-
therapy cycles. All serious adverse events and suspected unex-
pected serious adverse reactions (SUSARs) were reported to
the chief investigator within 24 h, as well as to the Royal
Marsden Research and Development ofﬁce in accordance
with the Royal Marsden Hospital Standard Operating
Procedures. In addition all SUSARs were reported to the
main Regional Ethics Committee and the Medicine and
Health Related Agency within the required timeframes.
STATISTICAL ANALYSIS
The primary end point of the trial was to detect a reduc-
tion in neutropenia with the addition of vitamins to
chemotherapy. The end points were analysed in an
intention-to-treat population. In order to detect a clinic-
ally meaningful reduction in neutropenia from a pre-
dicted incidence of 40% to an incidence of 10%, with
90% power, a total of 84 patients were required that is,
42 per treatment arm.
The maximum grade of neutropenia experienced
from the start of treatment until 30 days after the ﬁnal
course of treatment was calculated and tabulated by
randomised treatment and compared by means of χ2
(5% level of signiﬁcance was used). The proportion of
patients on each treatment arm experiencing grade 3–4
neutropenia was reported as a percentage with 95% CIs.
Non-neutropenic toxicity was tabulated by type of tox-
icity and by the worst grade experienced by each patient
and summarised by the proportion of patients experien-
cing a grade 3–4 toxicity. Analysis was as for the primary
end point (χ2) but a 1% level of signiﬁcance was used
because of the large number of treatment comparisons.
Death within 30 days of last chemotherapy was assessed
by the principal investigator with the information avail-
able. Overall survival (OS) for treatment groups was mea-
sured from randomisation until death from any cause.
Patients that were alive or lost to follow-up were censored
at last follow-up date. OS was illustrated by means of
Kaplan-Meier curves and the log rank statistic was used to
compare survival between treatment groups.
Differences in HC levels at baseline between treatment
groups A and B, and change from baseline HC levels
between treatment groups A and B were assessed by the
Mann-Whitney test.
QOL questionnaires were scored according to the
EORTC QLC30 scoring manual. Changes from baseline
(pretreatment) in the functional scales (physical, role,
emotional, cognitive, social) and in global health scale
were calculated at each timepoint (6 weeks and 3
monthly after the end of treatment). Difference between
treatment groups for mean change from baseline was
assessed by the Mann-Whitney test at each time point.
In a post hoc analysis the patients with a high baseline
HC levels and a ≥30% reduction with vitamin
Figure 1 Consort diagram.
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supplementation were considered to be ‘successfully sup-
plemented’. HC level and toxicity differences were com-
pared between groups and tested using Fishers exact test.
The study was undertaken with institutional review and
ethics approval and in accordance with the Principles of
Good Clinical Practice (GCP), the European Union and
GCP Directives (2001/20/EC; 2005/28/EC) and the
Medicines for Human Use (Clinical Trials) and Blood
Safety and Quality (Amendment) Regulations 2008
(Statutory Instrument 2008 No. 941). The study was
approved by the The Royal Marsden Local Research
Ethics Committee and was run on only one site. REC refer-
ence number 05/Q0801/178
RESULTS
Between September 2006 and February 2011 there were
84 patients recruited into the study; 41 to chemotherapy
with vitamin supplementation (arm A) and 43 to chemo-
therapy alone (arm B). One patient had myeloma and
was therefore excluded. As a result, a total of 83 patients
were considered for the ﬁnal analysis (ﬁgure 1—consort
diagram). In table 1, patient characteristics are shown
and were balanced for disease subtype, chemotherapy
used and ﬁrst-line and second-line therapies. There were
77 patients analysed for toxicity (the primary end point)
and 78 for QOL, OS and HC (ﬁgure 1).
Primary end point
The primary end point was the difference in grade 3/4
neutropenia and death within 30 days of treatment
between the treatment arms. χ2 Test for trend showed
no signiﬁcant difference between the arms (p=0.631).
The proportion of patients experiencing grade 3/4 neu-
tropenia or death within 30 days of treatment was 36%
in arm A (95% CI 26 to 48%) and 37% in arm B (95%
CI 22 to 53%). There were 3 deaths within 30 days of
treatment in arm A and one death in arm B. As a con-
ﬁrmatory analysis, rates of grade 3/4 neutropenia and
death within 30 days of treatment versus less than 3 neu-
tropenia toxicity were compared between treatment
arms using a χ2 test which was also non-signiﬁcant
(p=0.966), table 2.
Secondary end points
Non-neutropenic toxicities
For non-neutropenic toxicities in the secondary end
points, χ2 test for trend was used to assess differences
across the toxicity grades. Again as a conﬁrmatory ana-
lysis, rates of grade 3 or more versus less than grade 3
toxicity was compared between treatments using a χ2
test, as shown in table 3 nausea/vomiting was not signiﬁ-
cantly different by grade and no severe mucositis toxicity
grade 3–4 was reported. Other chemotherapy-related
toxicities were not signiﬁcantly different between treat-
ment groups. In the chemotherapy alone group, the
incidence of fatigue as a toxicity was signiﬁcantly lower
with vitamin supplementation (p=0.003). This result was
further explored but not conﬁrmed in the quality of life
data.
HC Data
The median level of HC at baseline was 13 (range 7–54
μmol/L). There was no signiﬁcant difference in HC
baseline levels between groups (p=0.9; table 4). Baseline
HC concentrations did not predict myelosuppression
with regards to the neutrophil count (p=0.75). There
were nine patients in arm A (25%) and two in arm B
(5%) reporting successful supplementation (at least a
30% decrease of raised HC baseline level). In a post hoc
analysis (successful supplementation) did predict less
neutropenia when compared to the unsupplemented
group (0% vs 69%; p=0.02). None of the nine
Table 1 Patient characteristics
Characteristic
Chemotherapy
+Vitamins (arm A)
N=40 (48%)
Chemotherapy
(arm B)
N=43 (52%)
Age at diagnosis (years)
Median (IQR) 61 (12) 60 (14)
Sex
Male 29 (72.5%) 24 (56%)
Female 11 (27.5%) 19 (44%)
Diagnosis
NSCLC 34 (85%) 39 (91%)
SCLC 3 (7.5%) 3 (7%)
Mesothelioma 3 (7.5%) 1 (2%)
Performance status at diagnosis
0 3 (7.5%) 2 (5%)
1 32 (80%) 36 (84%)
2 5 (12.5%) 5 (11%)
First-line
treatment
35 (87.5%) 39 (91%)
Second-line
treatment
5 (12.5%) 4 (9%)
NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.
Table 2 Grade 3/4 neutropenia and death within 30 days of treatment
Chemotherapy+vitamins
(arm A) Chemotherapy (arm B)
Number of
patients n=36 Per cent
Number of
patients N=41 Per cent p Value
Rates of grade 3/4 neutropenia and
death within 30 days of treatment
13 36 15 37 0.966
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successfully supplemented patients experienced neutro-
penia. Of the three deaths in arm A on or within 30
deaths of treatment, two occurred in the unsuccessfully
supplemented group and one in the successful supple-
mented group.
Survival
At the time of analysis, 61 out of 78 patients (78%) had
died or were lost to follow-up and 17 (22%) were alive.
There was no statistically signiﬁcant difference in survival
between the treatment groups with median survivals of
7.0 (chemotherapy alone) and 12.3 months (chemother-
apy and vitamin supplementation; p=0.41; ﬁgure 2).
Quality of life
Seventy-eight patients completed the quality of life forms.
The assessment did not show a signiﬁcant difference
between the treatment groups with regard to the mean
change from baseline at 6 weeks and from the baseline at
3 months (table 5). There was no difference in fatigue
levels on the quality of life scales (data not shown).
DISCUSSION
This single centre phase II study examined the impact
of vitamin supplementation on toxicities associated with
platinum-based cytotoxic treatment in patients with lung
cancer and the potential of HC level as a biomarker for
chemotherapy-induced toxicity. The study was negative
for its primary end point of decreased neutropenic tox-
icity in the group receiving vitamin supplementation.
Although the population was mixed, the majority of
patients in the study had advanced NSCLC and were
receiving ﬁrst-line chemotherapy. Overall, in comparison
with previous studies, there was a similar rate of toxicity
of 36–7% grade 3 and 4 neutropenia.2 3 The inclusion
of second line patients and patients with SCLC increases
the rates of neutropenia to around 40–66%, as previ-
ously reported.5 6
The parameters chosen for assessment of HC in this
study were taken from the literature in patients mostly
without cancer, although some series using pemetrexed
treatment of various types of lung cancer was also used.
Neutropenia in itself is sometimes just a paper labora-
tory value, toxicity not impacting on patient safety or
outcome. However grade 3 and 4 neutropenia often
leads to sepsis, decompensation and organ failure there-
fore is usually managed by delaying subsequent chemo-
therapy, immediate or subsequent prescription of
growth factors or antibiotics. Patients with poorer per-
formance status are at high risk of neutropenia grade 3
and 4, neutropenic sepsis and death.14 Growth factors
continue to be costly in many countries and an extra
burden on patients and staff administering the growth
factors. It is therefore appropriate to use grade 3 and 4
neutropenia as an end point in studies of toxicity. The
study was powered to show only a large difference in the
rate of neutropenia between the two arms (40–10%).
The supplemented patients showed no improvement in
the rate of neutropenia, which was around 36–7% in
both arms as predicted.
There are potential weaknesses with this study, com-
mensurate with a small, single centre phase II study. The
Table 3 Maximum common toxicity criteria grade 3/4 toxicities
Chemotherapy+vitamins (arm A) Chemotherapy (arm B)
Number of patients
n=36 Per cent
Number of patients
N=41 Per cent p Value
Infection 6 17 5 12 0.144
Nausea/vomiting 2 6 1 2 0.805
Diarrhoea 1 3 2 5 0.945
Constipation 1 3 0 0 0.572
Nephrotoxicity 1 3 0 0 0.516
Fatigue 4 11 3 7 0.003
Table 4 Homocysteine (HC) levels
HC at
baseline
HC at day 1 of
chemotherapy
HC change from
baseline
HC change from
baseline (%)
Chemotherapy+vitamins
(arm A)
N=36
N 32 20 20 20
Median (Range) 13.5 (7 to 25) 8.8 (5.1 to 22.7) −3.6 (−10.9 to –0.2) −25.4 (−59.8 to –2.8)
Chemotherapy (arm B)
N=42
N 37 23 23 23
Median (Range) 13.0 (7 to 54) 13.1 (5.9 to 46.7) −0.8 (−7 to 18.6) −4.4 (−48.2 to 229.6)
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study was unblinded and not placebo controlled.
However several points of interest are raised. First pre-
treatment homocysteine levels were high in this patient
population suggesting vitamin depletion levels are high
in this group. There may be other lifestyle factors
affecting homocysteine levels in this patient population
but the most likely factor is malnutrition, known to be
prevalent in this patient group. As such, management
and improvement of malnourishment should be
considered in the holistic approach to these patients.
Second, only 25% of patients in arm A showed evidence
of a successful response to vitamin B12 and folic acid as
determined by at least a 30% decrease in HC levels—
this has not been reported before. This was a novel
and unexpected ﬁnding and raises an important
question as to the optimal dose of vitamin supplementa-
tion. We used the standard dose commonly prescribed
in the setting of chemotherapy supplementation.
Further work on dose of folic acid and vitamin B12
and monitoring of homocysteine levels may be necessary
and useful.
In this study there was an unexpectedly small numbers
of successfully supplemented patients, suitable for a true
comparison of the intervention. In a post hoc analysis of
patients in arm A who were successfully supplemented,
there was less neutropenic toxicity compared to unsup-
plemented patients. This warrants further investigation.
If conﬁrmed as a biomarker HC levels could potentially
be used to select patients for growth factor use.
In the quality of life data there was a trend to
improved quality of life with vitamin supplementation in
the physical domain at 6 weeks and 3 months, emotional
domain at 3 months and new role, social and global
health at 6 weeks. As a non-statistically signiﬁcant trend
this needs to be interpreted with caution. Though ana-
lysis of OS showed no statistically signiﬁcant difference
between the two arms it is interesting to note that the
median survival of 12.3 months in the vitamin supple-
mented arm is higher than one might expect from this
patient group.
In conclusion, we failed to demonstrate that the use of
vitamin supplementation in unselected patients
Figure 2 Kaplan-Meier survival
estimate of treatment groups.
Table 5 Mean changes of functional scales
Mean change from baseline at 6 weeks Mean change from baseline at 3 months
Functional
scales
Chemotherapy
+vitamins (arm A)
Chemotherapy
(arm B) p Value
Chemotherapy
+vitamins (arm A)
Chemotherapy
(arm B) p Value
Physical −1.8 −10.2 0.251 5 −2.9 0.487
New role 0.0 −8.3 0.444 0.0 9.3 0.971
Emotional 7.5 4.2 0.484 6.3 3.7 0.685
Cognitive 7.2 −0.9 0.138 6.9 0.0 0.385
Social 2.2 −7.4 0.279 1.4 8.3 0.468
Global health 2.5 −7.1 0.399 5.6 0.9 0.943
The greater negative scores in the mean change representing a worse quality of life or functioning.
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improves the toxicity from platinum-based chemother-
apy. Future research is necessary on the dose and sched-
ule of vitamin B12 and folate supplementation to achieve
a decrease in HC levels in a greater proportion of
patients than was achievable with the schedule used in
this study. Interesting post hoc data was generated
regarding reduction in neutropenic toxicity in the small
group of successfully supplemented patients.
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